Hodgkin’s lymphoma symptoms: Signs of the cancer you should know
HODGKIN ’S lymphoma is a form of cancer which develops in the lymphatic system - which is part of the immune system.
CONCLUSIONS: Absolute numbers of cases of HL at our centre have increased since the roll-out of antiretroviral therapy (ART) to the public sector. The recent change in policy to make ART available to all HIV-positive patients independent of CD4+ count suggests that patients will survive longer and are therefore at increased risk of developing HL. We anticipate that numbers of HL cases will increase or remain high in the coming years, and we need to prepare for this. PMID: 30004343 [PubMed - in process]
Conclusions: Taken together, this work demonstrated that miR-181b might have the ability to overcome chemo resistance of small cell lung cancer cells, and restoration of this miRNA may represent a potential therapeutic strategy for improving chemo sensitivity in small cell lung cancer. PMID: 30002690 [PubMed]
I read with interest the proposal of the European Organisation for Research and Treatment of Cancer (EORTC) cutaneous lymphoma task force concerning B ratings based on absolute counts of CD4+CD26 − or CD4+CD7− lymphocytes, that is, B0,
The comments on blood class in erythrodermic cutaneous T-cell lymphoma (CTCL) from E. Vonderheid are received with interest by our European Organisation for Research and Treatment of Cancer (EORTC) group. First, it should be noted that our recent EORTC consensus statement defined blood class according to flow cytometry  and included all patients with mycosis fungoides (MF) and Sezary syndrome (SS). E. Vonderheid commented on blood class in erythrodermic MF/SS, and it must be recognised that blood involvement is much more frequent in erythrodermic CTCL than patch, plaque and tumour stage MF p
ConclusionsOur findings are not consistent with a discernable effect of cellphone use patterns in Israel on incidence trends of brain, CNS and intracranial tumors.
Conclusions: TP53 mutations reduce responsiveness to crizotinib and worsen prognosis in ALK rearrangement NSCLC patients. PMID: 29997966 [PubMed]
Condition: Lymphoma Intervention: Drug: Pembrolizumab Sponsor: Abramson Cancer Center of the University of Pennsylvania Recruiting
The glycoprotein CD56, also known as a neural cell adhesion molecule (NCAM), plays an important role in normal physiological functions. It is expressed in low levels in normal cells such as neurons, glia, skeletal muscle and natural killer cells. It is highly expressed on a variety of cancerous cells including those of neuroblastoma, small-cell lung cancer, and multiple myeloma. In neuroblastoma, patients undergo a very aggress ive standard of care regimen that results in a high mortality rate. Many neuroblastomas have increased expression of CD56, which represents a possible therapeutic target for these...
Work by theNanotechnology Characterization Laboratory (NCL), a joint initiative of NCI, NIST, and the FDA, has led to the discovery of a novel combination chemotherapy. This combination is shown to have synergistic effects on cytotoxicity to cancer cells in vitro, and to cause a substantial decrease in tumor growth in preclinical tumor models in vivo. Combination therapy using these agents may enhance the response rate of different cancers to these drugs and may significantly reduce side effects by permitting a lower therapeutic dose to be administered. SAIC Frederick'' s Nanotechnology Characterization Laboratory&n...
Abstract The natural history of mantle cell lymphoma (MCL) is a continuous process with the vicious cycle of remission and recurrence. Because MCL cells are most vulnerable before their exposure to therapeutic agents, front-line therapy could eliminate MCL cells at the first strike, reduce the chance for secondary resistance, and cause long-term remissions. If optimized, it could become an alternative to cure MCL. The key is the intensity of front-line therapy. Both the Nordic 2 and the MD Anderson Cancer Center HCVAD trials, with follow-up times greater than 10 years, achieved long-term survivals exceeding 1...